Author Archives: NeuroPerspective

The Enbrel Imbroglio: Finally, Some Genuinely ‘Fake News’

(we are making an exception to our ‘paywall’ policy due to the wide dissemination of the WaPo story discussed below) The Enbrel Imbroglio: Finally, Some Genuinely ‘Fake News’ “Pfizer had clues its blockbuster drug could prevent Alzheimer’s. Why didn’t it … Continue reading

Posted in Big Pharma, Muddled Media | Leave a comment

Neurogram+ and the Paywall 3 7 19

During the lengthy interregenum between Neurogram+ posts, we have decided that-like numerous content providers in the publishing industry-that it is time to upgrade Neurogram+‘s frequency, but to place it behind a paywall. To keep it straightforward, Neurogram+ will now only … Continue reading

Posted in Uncategorized | 1 Comment

Some observations regarding companies that should know better

Welcome to the Jurassic Petting Zoo Dinosaurs once roamed and ruled the earth, but they couldn’t take the heat. Similarly, Pfizer is exiting neuroscience R&D, with the exception of a couple of pain and rare disease programs, since they reside … Continue reading

Posted in Big Pharma, BioFollies, Biotech | Tagged , , , , , , , , , , | Leave a comment

An Unholy Trinity of Bad News

An Unholy Trinity of Bad News In descending order of Disappointment to Disgust: 1)SAGE Therapeutics  and Brexanolone in SRSE: When asked this year what nearterm clinical trial results inspired the most confidence for us, we often mentioned the SAGE Therapeutics … Continue reading

Posted in Uncategorized | Leave a comment

Notes from a Field Trip to the Medical Tower of Babel

NIR subscribers of long duration are well aware that we believe in first-hand data collection–who will forget the 1999 issue wherein we recounted our participation in the first cat-to-human brain transplant? (It didn’t take….sorry about that, Whiskers) Or last year’s … Continue reading

Posted in Uncategorized | 1 Comment

Pharma Shrugged

We take issue with the commonly-held view that pushing a drug price as much as the market will bear is a fiduciary and ethical obligation: Draining every possible penny from the health care ecosystem jeopardizes the longterm health of that … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , | Leave a comment

Pfallergan Round II?

<<Trump Executive Order Could Revive Allergan-Pfizer Merger -Emily Stewart    April 22,  2017 The Trump administration’s executive order on tax regulations could revive the defunct Allergan-Pfizer merger. The White House on Friday unveiled a new executive order instructing the Treasury … Continue reading

Posted in Big Pharma, BioFollies | Tagged , , , | 1 Comment

Assorted Interim Comments

1) Scott Gottlieb as FDA Commissioner: Gottlieb was Deputy Commissioner during the all-too-brief tenure of Mark McClellan, and we have followed his commentaries with interest and generally with agreement over the past decade+. We do believe that he has more … Continue reading

Posted in Big Pharma, Biotech, Muddled Media | Tagged , , , , , , , , | Leave a comment

Jeff Nye

It is with great sadness that we learned of the death of Jeffrey Nye, MD PhD, VP of Neuroscience Innovation at Johnson & Johnson. Jeff was a highly respected and effective voice for neuroscience within JNJ and the field, and will … Continue reading

Posted in Big Pharma | Tagged , , | Leave a comment

Parsley, SAGE, Marathon, and Timing

–with apologies to Simon and Garfunkel, 1966 SIDE A NIR has long been an admirer of how SAGE Therapeutics has been able to leverage predictive power from tiny pilot studies in Severe Status Epilepticus (SRSE) and Post-Partum Depression (PPD)—but today’s … Continue reading

Posted in BioFollies, Biotech | Tagged , , , | 1 Comment